Multithread effectively and personalize outreach to convert deals faster
Elevate social presence and drive business growth from social media
Identify and prioritize high-intent leads, and improve sales effectiveness
Find and connect with ICP attendees, and improve event outcomes
Geneos Therapeutics is a clinical-stage biopharmaceutical company pioneering the development of personalized, neoantigen-targeted immunotherapies for cancer. Their proprietary GT-EPIC™ (Geneos Therapeutics – Elicit, Prime, Immune, Cell) platform is designed to identify and target unique tumor mutations (neoantigens) specific to each patient. By creating custom-designed DNA-based therapies, Geneos aims to stimulate a patient's immune system to recognize and attack their individual cancer. Their lead programs are focused on treating advanced hepatocellular carcinoma (HCC) and other challenging cancers, often in combination with checkpoint inhibitors.
The headquarters serves as the central hub for Geneos Therapeutics' research and development, clinical operations, corporate administration, and strategic planning.
The facility likely includes modern laboratory spaces equipped for DNA plasmid development and immunological research, alongside corporate offices.
The work culture at Geneos Therapeutics is expected to be highly collaborative, science-driven, and patient-focused, with an emphasis on innovation and translational research in oncology.
Its location in the Philadelphia biotech corridor provides access to a rich ecosystem of research institutions, talent, and potential collaborators, crucial for a clinical-stage company.
While headquartered in the US, Geneos Therapeutics conducts clinical trials that may involve sites and patients internationally. Their collaborations and partnerships can also extend globally to advance their personalized cancer immunotherapy programs. Their primary operational presence is centered in the United States.
420 Plymouth Road, Suite 200
Plymouth Meeting
PA
USA
No additional office locations available.
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
As of April 2025, Geneos Therapeutics' leadership includes:
Geneos Therapeutics has been backed by several prominent investors over the years, including:
Based on publicly available information, Geneos Therapeutics has maintained a stable executive team over the past 12 months with no major publicly announced hires or departures at the senior executive level. The company continues to be led by its established leadership.
Discover the tools Geneos Therapeutics uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
Geneos Therapeutics likely uses standard corporate email formats. The most common formats typically involve combinations of first name, last name, and initials.
[first_initial][last]@geneostx.com
Format
jdoe@geneostx.com
Example
70%
Success rate
GlobeNewswire • October 24, 2023
Geneos Therapeutics announced the dosing of the first patient in its Phase 2 clinical trial (GT-30) evaluating GNOS-PV, a personalized cancer vaccine, in combination with Merck’s anti-PD-1 therapy, KEYTRUDA® (pembrolizumab), for patients with unresectable or metastatic advanced hepatocellular carcinoma (HCC) who have not received prior systemic therapy....more
GlobeNewswire • June 5, 2023
Geneos Therapeutics presented positive interim data from its ongoing Phase 1b/2a clinical trial (GT-20) of GNOS-PV02, a personalized cancer vaccine, in combination with pembrolizumab and DNA-encoded IL-12 (INO-9012) in patients with advanced hepatocellular carcinoma (HCC). The data highlighted robust neoantigen-specific T cell responses and encouraging clinical activity....more
See where a company’s workforce is located, by country or region.
View past and recent funding rounds with amounts and investors.
Understand company revenue estimates and financial scale.
Track active roles and hiring trends to spot growth signals.
Discover what a company offers—products, platforms, and solutions.
Get the company’s official SIC and NAICS classifications.
Analyze visitor volume, engagement, and top traffic sources.
Explore LinkedIn, Twitter, and other active social profiles.
Identify top competitors based on similar business traits.
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
Thousands of companies, including Geneos Therapeutics, are just a search away.